Activity of P-Glycoprotein, a β-Amyloid Transporter at the Blood–Brain Barrier, Is Compromised in Patients with Mild Alzheimer Disease
Open Access
- 19 May 2014
- journal article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 55 (7), 1106-1111
- https://doi.org/10.2967/jnumed.113.130161
Abstract
Studies in animals and postmortem human brain tissue support a role for P-glycoprotein in clearance of cerebral β-amyloid across the blood–brain barrier (BBB). We tested the hypothesis that BBB P-glycoprotein activity is diminished in Alzheimer disease (AD) by accounting for an AD-related reduction in regional cerebral blood flow (rCBF). Methods: We compared P-glycoprotein activity in mild-AD patients (n = 9) and cognitively normal, age-matched controls (n = 9) using PET with a labeled P-glycoprotein substrate, 11C-verapamil, and 15O-water to measure rCBF. BBB P-glycoprotein activity was expressed as the 11C-verapamil radioactivity extraction ratio (11C-verapamil brain distributional clearance, K1/rCBF). Results: Compared with controls, BBB P-glycoprotein activity was significantly lower in the parietotemporal, frontal, and posterior cingulate cortices and hippocampus of mild AD subjects. Conclusion: BBB P-glycoprotein activity in brain regions affected by AD is reduced and is independent of rCBF. This study improves on prior work by eliminating the confounding effect that reduced rCBF has on assessment of BBB P-glycoprotein activity and suggests that impaired P-glycoprotein activity may contribute to cerebral β-amyloid accumulation in AD. P-glycoprotein induction or activation to increase cerebral β-amyloid clearance could constitute a novel preventive or therapeutic strategy for AD.This publication has 40 references indexed in Scilit:
- Treating Alzheimer’s disease with monoclonal antibodies: current status and outlook for the futureAlzheimer's Research & Therapy, 2013
- Decreased Clearance of CNS β-Amyloid in Alzheimer’s DiseaseScience, 2010
- ABC efflux transporters in brain vasculature of Alzheimer's subjectsBrain Research, 2010
- Regional P-Glycoprotein Activity and Inhibition at the Human Blood–Brain Barrier as Imaged by Positron Emission TomographyClinical Pharmacology & Therapeutics, 2010
- Alzheimer's DiseaseThe New England Journal of Medicine, 2010
- Restoring Blood-Brain Barrier P-Glycoprotein Reduces Brain Amyloid-β in a Mouse Model of Alzheimer's DiseasePublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2010
- Positron emission tomography imaging of tissue P-glycoprotein activity during pregnancy in the non-human primateBritish Journal of Pharmacology, 2009
- Imaging of Cyclosporine Inhibition of P-Glycoprotein Activity Using 11C-Verapamil in the Brain: Studies of Healthy HumansJournal of Nuclear Medicine, 2009
- Synthesis and Evaluation of [N-methyl-11C]N-Desmethyl-loperamide as a New and Improved PET Radiotracer for Imaging P-gp FunctionJournal of Medicinal Chemistry, 2008
- Cerebral metabolic and cognitive studies in dementia with frontal lobe behavioral featuresJournal of Psychiatric Research, 1990